title: Doxazosin in the treatment of essential hypertension in general medical practice in Latin America.
abstract: This Latin American study assessed in the general practice setting the efficacy and tolerance of once-daily doxazosin in the treatment of mild or moderate essential hypertension (sitting diastolic blood pressure, 95 to 115 mm Hg). Patients (n = 220) were treated with doxazosin for 12 weeks as monotherapy or in combination with other antihypertensive agents. At the final visit, doxazosin produced a mean change in sitting systolic/diastolic blood pressure of -18.4/-14.4 mm Hg, at a mean daily dose of 4.3 mg. One hundred sixty-three (77.6%) of the 210 evaluable patients were considered a therapeutic success. Lipid analyses identified a statistically significant (p = 0.02) reduction in total serum cholesterol (4.85%) and an overall decrease in triglyceride levels (5.12%). According to the Framingham Heart Study equation, doxazosin produced a highly significant (p less than 0.001) 20% reduction in the calculated probability of developing coronary heart disease in 10 years. Of the 220 patients evaluated, 54 (24.5%) reported side effects that were considered related to treatment. Ten (4.5%) patients reported side effects unrelated to treatment and 37 (16.8%) reported events of unknown relationship. Most side effects were mild or moderate and were tolerated or disappeared with continued treatment. Nine patients (4.1%) were discontinued from therapy and in 13 (5.9%) the dose was reduced. The most prevalent side effects were headache and dizziness. The investigator's overall assessment of antihypertensive efficacy was excellent or good for 176 patients (80.4%); tolerance was considered excellent or good in 193 patients (88.5%).(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Pharmacology Department, Central University of Venezuela, Caracas.
authors.forename: H
authors.initials: H
authors.lastname: Silva
authors.forename: R
authors.initials: R
authors.lastname: Fonseca
authors.forename: D
authors.initials: D
authors.lastname: Marshall
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001118:Argentina / Q000453:epidemiology; D002784:Cholesterol / Q000097:blood; D003327:Coronary Disease / Q000453:epidemiology; D017292:Doxazosin; D005194:Family Practice; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D011224:Prazosin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012307:Risk Factors; D014687:Venezuela / Q000453:epidemiology
chemical_list: D000959:Antihypertensive Agents; D008055:Lipids; D002784:Cholesterol; D017292:Doxazosin; D011224:Prazosin